Nintedanib Takes the Lead: Slower FVC Decline in IPF Patients Compared to Pirfenidone
28 Nov 2023 • Antifibrotics are effective in slowing forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF). However, whether antifibrotic type is differentially associated with FVC decline has remained inconclusive.
In a comparative analysis, researchers evaluated the impact of pirfenidone and nintedanib on the decline of FVC in individuals with idiopathic pulmonary fibrosis (IPF).
- Patients with IPF who used nintedanib experienced a slower 12-month FVC decline than those on pirfenidone.
- Importantly, no significant differences were observed in overall survival or non-elective respiratory hospitalization between the two groups.
Source: CHEST | Read full story